TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02012712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Health Record (PHR)
Description: Iowa PHR is a Web-based application that features a tabbed interface design. Users can enter, view, and print their current and past medicines, allergies, health conditions, and health event tracking over time. An embedded tutorial video provides assistance with the system. The PHR was developed and refined using participatory design and focus group sessions as well as evaluation in a usability laboratory. The resulting design emphasizes the reduction of physical and cognitive demands on users, focusing on simplicity, readability, and quick navigation.~Iowa PHR displayed a message when a user entered a medication with an associated Assessing Care of Vulnerable Elders project (ACOVE-3) safety concern. This included 16 safety issues for 12 drugs or drug classes with safety concerns. We also adapted four general medication use patient safety indicators from the ACOVE project and displayed them to all users on a rotating basis upon login.
Study: NCT02215824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIWH 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04380805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: All subjects will receive AK104 as a single agent at a dose of 6 mg/kg Q2W (Day 1 and Day 15 of each 28 day treatment cycle) via IV infusion.
Study: NCT03281083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium
Study: NCT00934674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-606 (Bosutinib)
Description: Arm 1 - Commercial Tablet manufactured by Excella~Arm 2 - Clinical Tablet manufactured by Wyeth Montreal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-606 (Bosutinib)
Description: Arm 1 - Commercial Tablet manufactured by Excella~Arm 2 - Clinical Tablet manufactured by Wyeth Montreal
Study: NCT01477112

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Betacarotene
Description: 6 mg betacarotene in caplets for 45 days (daily)and reevaluate parameters 30 days after finishing supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betacarotene
Description: 6 mg betacarotene in caplets for 45 days (daily)and reevaluate parameters 30 days after finishing supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Controls. No treatment
Description: Evaluate at time 0, 45 days and 75 days, but without receiving betacarotene supplements

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Controls. No treatment
Description: Evaluate at time 0, 45 days and 75 days, but without receiving betacarotene supplements
Study: NCT01706783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: Subcutaneous (s.c., under the skin) administration once weekly (Days 1, 8, 15 and 22) of 4 different doses of NNC0195-0092 (somapacitan) in an escalating order

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin NordiFlex®
Description: Subcutaneous (s.c., under the skin) administration daily for 28 days. The daily dosing will be the same as the pre-trial daily dose of human growth hormone (hGH) taken by the adult with growth hormone deficiency
Study: NCT01914653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silk surgical mesh
Description: A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silk surgical mesh
Description: A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silk surgical mesh
Description: A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
Study: NCT00620113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Odanacatib tablets 10 mg, 25 mg, or 50 mg (depending upon randomization), taken orally once weekly for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Odanacatib tablets 10 mg, 25 mg, or 50 mg (depending upon randomization), taken orally once weekly for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Odanacatib
Description: Odanacatib tablets 10 mg, 25 mg, or 50 mg (depending upon randomization), taken orally once weekly for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Two Vitamin D3 tablets (5600 IU total) taken orally once weekly for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Two Vitamin D3 tablets (5600 IU total) taken orally once weekly for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Two Vitamin D3 tablets (5600 IU total) taken orally once weekly for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Two Vitamin D3 tablets (5600 IU total) taken orally once weekly for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Calcium carbonate 500 mg tablet taken orally every day for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Calcium carbonate 500 mg tablet taken orally every day for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate
Description: Calcium carbonate 500 mg tablet taken orally every day for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate
Description: Calcium carbonate 500 mg tablet taken orally every day for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo tablets to odanacatib, taken orally once weekly for 52 weeks.
Study: NCT02973516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277 at 0.1 mmol/kg
Description: P03277 will be administered at 0.1 mmol/kg BW (corresponding to 0.2 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277 at 0.05 mmol/kg
Description: P03277 will be administered at 0.05 mmol/kg BW (corresponding to 0.1 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
Study: NCT03994198

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-lactalbumin
Description: A protein fraction of whey protein, higher in tryptophan

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen peptides
Description: Collagen peptides from bovine sources
Study: NCT03913494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transoral Neurostimulation Device (Snoozeal)
Description: Use of the Transoral Neurostimulation Device for 20 minutes, morning and night, every day for at least 4 weeks.
Study: NCT02461745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ombitasvir, paritaprevir/r, dasabuvir + ribavirin
Description: VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) + RBV (ribavirin tablets) for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ombitasvir, paritaprevir/r, dasabuvir
Description: VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets)
Study: NCT00688272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Given 500mg BID x 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Given QD x 6 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given QD x 6 days
Study: NCT01879943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam Colon 2
Description: PillCam® COLON 2 capsule endoscopy is a minimally invasive tool for direct visualization of the colon, including identifying the occurrence of polyps.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Standard colonoscopy is the standard against which capsule endoscopy is compared.
Study: NCT03470753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Number of Exercises
Description: Subjects will receive either 2 or 4 exercises to evaluate the short-term recall and performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Number of Exercises
Description: Subjects will receive either 2 or 4 exercises to evaluate the short-term recall and performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Type of Instruction
Description: The type of instruction in phase 1 will be compared: Instruction by providing a handout only vs being instructed by a provider and practiced by the patient with provider feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Type of Instruction
Description: The type of instruction in phase 1 will be compared: Instruction by providing a handout only vs being instructed by a provider and practiced by the patient with provider feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delivery Type
Description: In phase 2 subjects will be provided 4 exercises using only a handout vs delivered to them electronically with the addition of a video.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delivery Type
Description: In phase 2 subjects will be provided 4 exercises using only a handout vs delivered to them electronically with the addition of a video.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Reminder
Description: A text-message based mobile reminder tool will be utilized to engage with subjects via texting on a daily basis to provide reminders and encouragement to perform their home exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Reminder
Description: A text-message based mobile reminder tool will be utilized to engage with subjects via texting on a daily basis to provide reminders and encouragement to perform their home exercises.
Study: NCT03154749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)
Description: All eligible patients were randomly assigned at a 1:1 ratio to the experimental arm (docetaxel (75 mg/m2 administered intravenously every 3 weeks) plus carboplatin (AUC 6 mg/mL per min, intravenously every 3 weeks) for six cycles) or the standard treatment arm (epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2), both administered intravenously every 3 weeks for four cycles, followed by docetaxel (100 mg/m2) administered intravenously every 3 weeks for four cycles).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)
Description: All eligible patients were randomly assigned at a 1:1 ratio to the experimental arm (docetaxel (75 mg/m2 administered intravenously every 3 weeks) plus carboplatin (AUC 6 mg/mL per min, intravenously every 3 weeks) for six cycles) or the standard treatment arm (epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2), both administered intravenously every 3 weeks for four cycles, followed by docetaxel (100 mg/m2) administered intravenously every 3 weeks for four cycles).
Study: NCT03750643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3454738
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3454738
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3454738
Description: Administered IV
Study: NCT01219686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram, pindolol
Description: escitalopram p.o., once daily, day 1-2: 10mg, days 3-42: 20mg pindolol p.o., twice daily 7.5 mg days 1-14, once daily 7.5 mg days 15-17

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: escitalopram p.o., once daily. days 1-2: 10 mg, days 3-4: 20 mg, days 5-42: 30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: escitalopram 20 mg, p.o., once daily. Days 1-2: 10mg, days 3-42: 20 mg
Study: NCT02196792

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ArComXL liner
Description: ArComXL liner with a titanium cup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 32 mm femoral head
Description: Stem with a 32 mm CoCr femoral head
Study: NCT01406041

Intervention type: BIOLOGICAL
Intervention: Chemical and physical detection
Description: CVP, Urine volume per day, Blood electrolytes, Urine sodium per day, Pituitrin
Study: NCT03511781

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Description: Palliative Hypofractionated radiotherapy 35 GY in 10 fractions over 2 weeks in advanced incurable Breast Cancer
Study: NCT04480957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 Dose 1
Description: ARCT-021 Dose 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 Dose 2
Description: ARCT-021 Dose 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
Study: NCT02196792

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 32 mm femoral head
Description: Stem with a 32 mm CoCr femoral head

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 36 mm femoral head
Description: Stem with a 36 mm CoCr femoral head

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 36 mm femoral head
Description: Stem with a 36 mm CoCr femoral head
Study: NCT02360163

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Landmark Technique (TLT)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound guided peripheral intravenous access (USGPIVA)
Study: NCT03005821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chinese pediatric massage therapy + usual care

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham massage therapy + usual care
Study: NCT02886390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ischemic conditioning
Description: In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
Study: NCT04480957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 Dose 3
Description: ARCT-021 Dose 3 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 Dose 4
Description: ARCT-021 Dose 4 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 Dose Regimen 1
Description: ARCT-021 dose regimen 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 Dose Regimen 1
Description: ARCT-021 dose regimen 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 Dose Regimen 2
Description: ARCT-021 dose regimen 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
Study: NCT03488979

Intervention type: OTHER
Intervention: educational interventional group
Description: • Patient Education Tool (Appendix 3) and the patient's own IVC images will be shared with each patient in the intervention group in real time. If feasible, each intervention patient will also receive a printed copy of his or her IVC image.
Study: NCT04480957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 Dose Regimen 2
Description: ARCT-021 dose regimen 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile 0.9% saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile 0.9% saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile 0.9% saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile 0.9% saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile 0.9% saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile 0.9% saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile 0.9% saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile 0.9% saline
Study: NCT02055079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Fixed oral dose of 3 mg sirolimus (blinded) once weekly for 24 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fixed oral dose of 3 mg placebo (blinded) once weekly for 24 months.
Study: NCT03530644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WM3.4NR
Description: The investigational medical device will collect spectral Raman data from tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P0.1
Description: The investigational medical device will collect spectral Raman data from tissue.
Study: NCT03073902

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid biopsy
Description: Liquid biopsy
Study: NCT03875729

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: teplizumab
Description: Treatment

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control
Study: NCT03000725

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Using Practice and Learning to Increase Favorable Thoughts
Description: Description of the UPLIFT program: Participants who choose to participate in UPLIFT will complete 8 weekly group sessions via telephone.~Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping \& Relaxing Session 4: Attention \& Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure \& the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
Study: NCT01448928

Intervention type: DRUG
Intervention: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
Description: Patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma.
Study: NCT01474759

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice on diet, physical activity, and behavior change
Description: Individuals will participate in individual sessions with Registered Dietitians providing basic instruction in principles of weight loss. The program will instruct individuals on the principles of healthy eating and nutrition during calorie restriction. These materials include one module with general information on the importance of limiting portion sizes. The program will also include instruction on physical activity and behavioral strategies for weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advice on diet, physical activity, and behavior change
Description: Individuals will participate in individual sessions with Registered Dietitians providing basic instruction in principles of weight loss. The program will instruct individuals on the principles of healthy eating and nutrition during calorie restriction. These materials include one module with general information on the importance of limiting portion sizes. The program will also include instruction on physical activity and behavioral strategies for weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advice on diet, physical activity, and behavior change
Description: Individuals will participate in individual sessions with Registered Dietitians providing basic instruction in principles of weight loss. The program will instruct individuals on the principles of healthy eating and nutrition during calorie restriction. These materials include one module with general information on the importance of limiting portion sizes. The program will also include instruction on physical activity and behavioral strategies for weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instruction in food portion size
Description: Individuals assigned to this program will participate in individual instructional sessions with specialized materials and tools that address food selection and choosing appropriate portion sizes of various foods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provision of pre-portioned foods
Description: Individuals assigned to this program will be provided with commercially available pre-portioned foods and will be taught effective ways to incorporate them into their daily diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice on healthy eating for weight loss
Description: Individuals assigned to this program will participate in individual instructional sessions that address principles of healthy eating while on a calorie-restricted diet.
Study: NCT03210025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF-Methyldopa 250mg Tablet
Description: BF-Methyldopa 250mg Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
Study: NCT03750643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3454738
Description: Administered SC